Thromboelastographic study of fibrinolytic agents.
Summaria
L
L
Armour Pharmaceuticals, Kankakee, Illinois 60901, USA.
D005337:Fibrin / Q000187:drug effects; D005342:Fibrinolysis / Q000187:drug effects*; D005343:Fibrinolytic Agents / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use; D006470:Hemorrhage / Q000139:chemically induced / Q000517:prevention & control; D006801:Humans; D007518:Isoantibodies / Q000097:blood / Q000276:immunology; D010949:Plasma; D010960:Plasminogen Activators / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D012008:Recurrence; D012015:Reference Standards; D013300:Streptokinase / Q000009:adverse effects / Q000276:immunology / Q000494:pharmacology / Q000627:therapeutic use; D013916:Thrombelastography; D013923:Thromboembolism / Q000097:blood / Q000188:drug therapy*
D005343:Fibrinolytic Agents; D007518:Isoantibodies; D005337:Fibrin; D013300:Streptokinase; D010960:Plasminogen Activators